Assessment and treatment of movement disorders in children with cerebral palsy

Orthopedic Clinics of North America

Volumn 41, Issue 4, 2010, Pages 507-517

  Deon, Laura L ^a   Gaebler Spira Deborah, D ^a  

^a REHABILITATION INSTITUTE OF CHICAGO   (United States)

Author keywords

Cerebral palsy; Dystonia; Management; Pediatric; Spasticity; Treatment

Indexed keywords

ALCOHOL; BACLOFEN; BENZODIAZEPINE DERIVATIVE; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CARBIDOPA; CLONAZEPAM; DANTROLENE; DIAZEPAM; LEVODOPA; PHENOL; TIZANIDINE; TRIHEXYPHENIDYL; BENZODIAZEPINE RECEPTOR AFFECTING AGENT; MUSCLE RELAXANT AGENT;

ANHIDROSIS; ANXIETY; ASHWORTH SCALE; ATAXIA; ATTENTION DISTURBANCE; BARRY ALBRIGHT DYSTONIA SCALE; BEDTIME DOSAGE; BLEPHAROSPASM; BLURRED VISION; BRADYKINESIA; BRAIN DEPTH STIMULATION; CEREBRAL PALSY; CERVICAL DYSTONIA; CHILD; CHILDHOOD; CLINICAL FEATURE; CLONUS; CONFUSION; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DIZZINESS; DORSAL RHIZOTOMY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSESTHESIA; DYSKINESIA; DYSPHAGIA; DYSTONIA; ELECTROMYOGRAPHY; EVENING DOSAGE; FOCAL DYSTONIA; FUNCTIONAL ASSESSMENT; GLAUCOMA; HALLUCINATION; HEMATOMA; HEMIPLEGIA; HUMAN; HYPERHIDROSIS; HYPERSALIVATION; HYPOTENSION; INJECTION SITE PAIN; INSOMNIA; LIVER FUNCTION TEST; LIVER TOXICITY; MALAISE; MEMORY DISORDER; MOTOR DYSFUNCTION; MUSCLE HYPERTONIA; MUSCLE HYPOTONIA; MUSCLE RIGIDITY; MUSCLE SPASM; MUSCLE TONE; MUSCLE WEAKNESS; MYOFASCIAL PAIN; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; NEUROSURGERY; NIGHTMARE; OUTCOME ASSESSMENT; PARESTHESIA; PHYSIOTHERAPY; PRIORITY JOURNAL; RATING SCALE; RESPIRATORY TRACT DISEASE; REVIEW; RISK BENEFIT ANALYSIS; SEDATION; SIDE EFFECT; SPASTICITY; SPINAL CORD INJURY; STRABISMUS; TARDIEU SCALE; TARDIVE DYSKINESIA; TRAUMATIC BRAIN INJURY; TREATMENT PLANNING; URINE RETENTION; VOMITING; XEROSTOMIA; COMPLICATION; DRUG ADMINISTRATION ROUTE; MOTOR ACTIVITY; MOVEMENT DISORDERS; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME;

CEREBRAL PALSY; CHILD; DRUG ADMINISTRATION ROUTES; GABA MODULATORS; HUMANS; MOTOR ACTIVITY; MOVEMENT DISORDERS; NEUROMUSCULAR AGENTS; NEUROSURGICAL PROCEDURES; PHYSICAL THERAPY MODALITIES; TREATMENT OUTCOME;

EID: 77956925975     PISSN: 00305898     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ocl.2010.06.001     Document Type: Review

References (59)

1. Little W.J. On the influence of abnormal parturition, difficult labours, premature birth, and asphyxia neonatorum, on the mental and physical condition of the child, especially in relation to deformities. Clin Orthop Relat Res 1966, 46:7-22.
2. Tervo R.C., Azuma S., Stout J., et al. Correlation between physical functioning and gait measures in children with cerebral palsy. Dev Med Child Neurol 2002, 44(3):185-190.
3. Sanger T.D., Delgado M.R., Gaebler-Spira D., et al. Classification and definition of disorders causing hypertonia in childhood. Pediatrics 2003, 111(1):e89-e97.
4. Sanger T.D. Toward a definition of childhood dystonia. Curr Opin Pediatr 2004, 16(6):623-627.
5. Ito J., Araki A., Tanaka H., et al. Muscle histopathology in spastic cerebral palsy. Brain Dev 1996, 18(4):299-303.
6. Hoon A.H., Stashinko E.E., Nagae L.M., et al. Sensory and motor deficits in children with cerebral palsy born preterm correlate with diffusion tensor imaging abnormalities in thalamocortical pathways. Dev Med Child Neurol 2009, 51(9):697-704.
7. Fahn S. Concept and classification of dystonia. Adv Neurol 1988, 50:1-8.
8. Albanese A. The clinical expression of primary dystonia. J Neurol 2003, 250(10):1145-1151.
9. Marsden C.D. The pathophysiology of movement disorders. Neurol Clin 1984, 2(3):435-459.
10. Sanger T.D. Childhood onset generalised dystonia can be modelled by increased gain in the indirect basal ganglia pathway. J Neurol Neurosurg Psychiatr 2003, 74(11):1509-1515.
11. Fenichel G.M. Clinical pediatric neurology: a signs and symptoms approach 2009, Saunders/Elsevier, Philadelphia, p. ix, 415. 6th edition.
12. Scholtes V.A., Becher J.G., Beelen A., et al. Clinical assessment of spasticity in children with cerebral palsy: a critical review of available instruments. Dev Med Child Neurol 2006, 48(1):64-73.
13. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964, 192:540-542.
14. Bohannon R.W., Smith M.B. Interrater reliability of a Modified Ashworth Scale of muscle spasticity. Phys Ther 1987, 67(2):206-207.
15. Peacock W.J., Staudt L.A. Functional outcomes following selective posterior rhizotomy in children with cerebral palsy. J Neurosurg 1991, 74(3):380-385.
16. Tardieu G., Shentoub S., Delarue R. Rev Neurol (Paris) 1954, 91(2):143-144. [in French].
17. Boyd R. Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsy. Eur J Neurol 1999, 6(Suppl 4):S23-S35.
18. Barry M.J., VanSwearingen J.M., Albright A.L. Reliability and responsiveness of the Barry-Albright Dystonia Scale. Dev Med Child Neurol 1999, 41(6):404-411.
19. Wiart L., Darrah J., Kembhavi G. Stretching with children with cerebral palsy: what do we know and where are we going?. Pediatr Phys Ther 2008, 20(2):173-178.
20. Pin T., Dyke P., Chan M. The effectiveness of passive stretching in children with cerebral palsy. Dev Med Child Neurol 2006, 48(10):855-862.
21. Gracies J.M., Elovic E., McGuire J., et al. Traditional pharmacological treatments for spasticity. Part II: general and regional treatments. Muscle Nerve Suppl 1997, 6:S92-120.
22. Mathew A., Mathew M.C. Bedtime diazepam enhances well-being in children with spastic cerebral palsy. Pediatr Rehabil 2005, 8(1):63-66.
23. Mathew A., Mathew M.C., Thomas M., et al. The efficacy of diazepam in enhancing motor function in children with spastic cerebral palsy. J Trop Pediatr 2005, 51(2):109-113.
24. Patel D.R., Soyode O. Pharmacologic interventions for reducing spasticity in cerebral palsy. Indian J Pediatr 2005, 72(10):869-872.
25. Verrotti A., Greco R., Spalice A., et al. Pharmacotherapy of spasticity in children with cerebral palsy. Pediatr Neurol 2006, 34(1):1-6.
26. Krach L.E. Pharmacotherapy of spasticity: oral medications and intrathecal baclofen. J Child Neurol 2001, 16(1):31-36.
27. Sanger T.D. Pathophysiology of pediatric movement disorders. J Child Neurol 2003, 18(Suppl 1):S9-24.
28. Terrence C.F., Fromm G.H. Complications of baclofen withdrawal. Arch Neurol 1981, 38(9):588-589.
29. Saulino M., Jacobs B.W. The pharmacological management of spasticity. J Neurosci Nurs 2006, 38(6):456-459.
30. Glenn M.B., Whyte J. The practical management of spasticity in children and adults 1990, Lea & Febiger, Philadelphia, p. xii, 325.
31. Utili R., Boitnott J.K., Zimmerman H.J. Dantrolene-associated hepatic injury. Incidence and character. Gastroenterology 1977, 72(4 Pt 1):610-616.
32. Young R.R. Spasticity: a review. Neurology 1994, 44(11 Suppl 9):S12-S20.
33. Tilton A. Management of spasticity in children with cerebral palsy. Semin Pediatr Neurol 2009, 16(2):82-89.
34. Tilton A.H. Therapeutic interventions for tone abnormalities in cerebral palsy. NeuroRx 2006, 3(2):217-224.
35. Tilton A.H. Approach to the rehabilitation of spasticity and neuromuscular disorders in children. Neurol Clin 2003, 21(4):853-881. vii.
36. Graham H.K., Aoki K.R., Autti-Rämö I., et al. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture 2000, 11(1):67-79.
37. Graham H.K. Botulinum toxin type A management of spasticity in the context of orthopaedic surgery for children with spastic cerebral palsy. Eur J Neurol 2001, 8(Suppl 5):30-39.
38. Booth M.Y., Yates C.C., Edgar T.S., et al. Serial casting vs combined intervention with botulinum toxin A and serial casting in the treatment of spastic equinus in children. Pediatr Phys Ther 2003, 15(4):216-220.
39. Arens L.J., Peacock W.J., Peter J. Selective posterior rhizotomy: a long-term follow-up study. Childs Nerv Syst 1989, 5(3):148-152.
40. Fasano V.A., Broggi G., Barolat-Romana G., et al. Surgical treatment of spasticity in cerebral palsy. Childs Brain 1978, 4(5):289-305.
41. Peacock W., Staudt L. Selective posterior rhizotomy: history and results. Neurosurgery 1989, 4(2):403-408.
42. Lynn A.K., Turner M., Chambers H.G. Surgical management of spasticity in persons with cerebral palsy. PM R 2009, 1(9):834-838.
43. Lazareff J.A., Garcia-Mendez M.A., De Rosa R., et al. Limited (L4-S1, L5-S1) selective dorsal rhizotomy for reducing spasticity in cerebral palsy. Acta Neurochir (Wien) 1999, 141(7):743-751. [discussion: 751-2].
44. Engsberg J.R., Ross S.A., Park T.S. Changes in ankle spasticity and strength following selective dorsal rhizotomy and physical therapy for spastic cerebral palsy. J Neurosurg 1999, 91(5):727-732.
45. Albright A.L., Cervi A., Singletary J. Intrathecal baclofen for spasticity in cerebral palsy. JAMA 1991, 265(11):1418-1422.
46. Gilmartin R., Bruce D., Storrs B.B., et al. Intrathecal baclofen for management of spastic cerebral palsy: multicenter trial. J Child Neurol 2000, 15(2):71-77.
47. Van Schaeybroeck P., Nuttin B., Lagae L., et al. Intrathecal baclofen for intractable cerebral spasticity: a prospective placebo-controlled, double-blind study. Neurosurgery 2000, 46(3):603-609. [discussion: 609-12].
48. Langlois M., Richer F., Chouinard S. New perspectives on dystonia. Can J Neurol Sci 2003, 30(Suppl 1):S34-S44.
49. Bressman S.B. Dystonia update. Clin Neuropharmacol 2000, 23(5):239-251.
50. Pranzatelli M.R. Movement disorders in childhood. Pediatr Rev 1996, 17(11):388-394.
51. Adler C.H. Strategies for controlling dystonia. Overview of therapies that may alleviate symptoms. Postgrad Med 2000, 108(5):151-152. 155-6, 159-60.
52. Hallett M., Glocker F.X., Deuschl G. Mechanism of action of botulinum toxin. Ann Neurol 1994, 36(3):449-450.
53. Ford B., Greene P., Louis E.D., et al. Use of intrathecal baclofen in the treatment of patients with dystonia. Arch Neurol 1996, 53(12):1241-1246.
54. Ford B., Greene P.E., Louis E.D., et al. Intrathecal baclofen in the treatment of dystonia. Adv Neurol 1998, 78:199-210.
55. Krack P., Vercueil L. Review of the functional surgical treatment of dystonia. Eur J Neurol 2001, 8(5):389-399.
56. Pollak P. Neurosurgical treatment of dyskinesias: pathophysiological consideration. Mov Disord 1999, 14(Suppl 1):33-39.
57. Volkmann J., Benecke R. Deep brain stimulation for dystonia: patient selection and evaluation. Mov Disord 2002, 17(Suppl 3):S112-S115.
58. Cosgrove A.P., Corry I.S., Graham H.K. Botulinum toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol 1994, 36(5):386-396.
59. Koman L.A., Mooney J.F., Smith B., et al. Management of cerebral palsy with botulinum-A toxin: preliminary investigation. J Pediatr Orthop 1993, 13(4):489-495.